Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ViPOR-P in Relapsed/Refractory B-cell Lymphoma
NCT04739813Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of polatuzumab vedotin and venetoclax in B cell lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number and grade of adverse events at 21 days and Complete response rate. Started Jul 2021; status: active, not recruiting.
02
Drugs
polatuzumab vedotinvenetoclax
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04739813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739813.